146 related articles for article (PubMed ID: 15100315)
1. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H
J Immunol; 2004 May; 172(9):5702-6. PubMed ID: 15100315
[TBL] [Abstract][Full Text] [Related]
2. Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis.
Niculescu T; Weerth S; Soane L; Niculescu F; Rus V; Raine CS; Shin ML; Rus H
Ann N Y Acad Sci; 2003 Dec; 1010():530-3. PubMed ID: 15033785
[TBL] [Abstract][Full Text] [Related]
3. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.
Weerth SH; Rus H; Shin ML; Raine CS
Am J Pathol; 2003 Sep; 163(3):1069-80. PubMed ID: 12937147
[TBL] [Abstract][Full Text] [Related]
4. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
Rus H; Cudrici C; Niculescu F
Ann Med; 2005; 37(2):97-104. PubMed ID: 16026117
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
Tegla CA; Cudrici C; Rus V; Ito T; Vlaicu S; Singh A; Rus H
J Neuroimmunol; 2009 Aug; 213(1-2):3-11. PubMed ID: 19577811
[TBL] [Abstract][Full Text] [Related]
6. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
Mc Guire C; Volckaert T; Wolke U; Sze M; de Rycke R; Waisman A; Prinz M; Beyaert R; Pasparakis M; van Loo G
J Immunol; 2010 Dec; 185(12):7646-53. PubMed ID: 21068410
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis.
Mokhtarian F; Safavi F; Sarafraz-Yazdi E
Brain Res; 2012 Dec; 1488():92-103. PubMed ID: 23031637
[TBL] [Abstract][Full Text] [Related]
8. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice.
Malipiero U; Frei K; Spanaus KS; Agresti C; Lassmann H; Hahne M; Tschopp J; Eugster HP; Fontana A
Eur J Immunol; 1997 Dec; 27(12):3151-60. PubMed ID: 9464800
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement.
Cudrici C; Niculescu T; Niculescu F; Shin ML; Rus H
J Rehabil Res Dev; 2006; 43(1):123-32. PubMed ID: 16847778
[TBL] [Abstract][Full Text] [Related]
10. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis.
Cudrici C; Ito T; Zafranskaia E; Weerth S; Rus V; Chen H; Niculescu F; Soloviova K; Tegla C; Gherman A; Raine CS; Shin ML; Rus H
J Neuroimmunol; 2008 Oct; 203(1):94-103. PubMed ID: 18692252
[TBL] [Abstract][Full Text] [Related]
11. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP.
Cudrici C; Niculescu F; Jensen T; Zafranskaia E; Fosbrink M; Rus V; Shin ML; Rus H
J Immunol; 2006 Mar; 176(5):3173-80. PubMed ID: 16493077
[TBL] [Abstract][Full Text] [Related]
12. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
[TBL] [Abstract][Full Text] [Related]
13. Fas system up-regulation in experimental autoimmune encephalomyelitis.
Ouallet J; Baumann N; Marie Y; Villarroya H
J Neurol Sci; 1999 Nov; 170(2):96-104. PubMed ID: 10561524
[TBL] [Abstract][Full Text] [Related]
14. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.
Suvannavejh GC; Dal Canto MC; Matis LA; Miller SD
J Clin Invest; 2000 Jan; 105(2):223-31. PubMed ID: 10642601
[TBL] [Abstract][Full Text] [Related]
15. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.
Waldner H; Sobel RA; Howard E; Kuchroo VK
J Immunol; 1997 Oct; 159(7):3100-3. PubMed ID: 9317104
[TBL] [Abstract][Full Text] [Related]
16. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system.
Du C; Sriram S
J Immunol; 2002 Mar; 168(6):3105-12. PubMed ID: 11884485
[TBL] [Abstract][Full Text] [Related]
17. The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis.
White CA; McCombe PA; Pender MP
J Neuroimmunol; 1998 Feb; 82(1):47-55. PubMed ID: 9526845
[TBL] [Abstract][Full Text] [Related]
18. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
Wen J; Ribeiro R; Tanaka M; Zhang Y
Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
[TBL] [Abstract][Full Text] [Related]
19. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis.
Teige A; Teige I; Lavasani S; Bockermann R; Mondoc E; Holmdahl R; Issazadeh-Navikas S
J Immunol; 2004 Jan; 172(1):186-94. PubMed ID: 14688325
[TBL] [Abstract][Full Text] [Related]
20. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system.
Sabelko KA; Kelly KA; Nahm MH; Cross AH; Russell JH
J Immunol; 1997 Oct; 159(7):3096-9. PubMed ID: 9317103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
